Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ...
Paul Mahon, EVP & GENERAL COUNSEL of United Therapeutics Corp (NASDAQ:UTHR), sold 6,000 shares of the company on March 21, 2024, according to a recent SEC filing. The transaction was executed at an average price of $236.45 per share, resulting in a total value of $1,418,700.
United Therapeutics Corp is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company's primary focus is on the development of therapies for pulmonary arterial hypertension (PAH) and other orphan diseases.
Over the past year, Paul Mahon has sold a total of 140,500 shares of United Therapeutics Corp and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of 53 insider sells and no insider buys over the past year.
Shares of United Therapeutics Corp were trading at $236.45 on the day of the insider's recent sale, giving the company a market capitalization of $11.195 billion. The price-earnings ratio of the company stands at 11.99, which is lower than the industry median of 29.46 and also below the company's historical median price-earnings ratio.
According to the GuruFocus Value assessment, with a current price of $236.45 and a GF Value of $270.60, United Therapeutics Corp has a price-to-GF-Value ratio of 0.87, indicating that the stock is modestly undervalued. The GF Value is an intrinsic value estimate that considers historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling activity for United Therapeutics Corp.
The GF Value image above provides a visual representation of the stock's valuation relative to its intrinsic value as estimated by GuruFocus.
For more detailed information on insider transactions and stock performance for United Therapeutics Corp (NASDAQ:UTHR), investors and analysts are encouraged to visit the SEC filing and the company's profile on GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
